Actively Recruiting

Age: 21Years - 70Years
All Genders
NCT06569589

Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

Led by Jens Titze · Updated on 2025-06-06

80

Participants Needed

4

Research Sites

139 weeks

Total Duration

On this page

Sponsors

J

Jens Titze

Lead Sponsor

C

Changi General Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.

CONDITIONS

Official Title

Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

Who Can Participate

Age: 21Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 21-70 years with arterial hypertension or suspected primary aldosteronism based on guidelines
  • Male and female patients older than 21 years
  • Willingness to participate and ability to provide informed consent
Not Eligible

You will not qualify if you...

  • Presence of implanted devices (surgical clips, pacemakers, defibrillators, cochlear implants) or metal not safe for MRI
  • Iron-based tattoos
  • Noticeable anxiety or claustrophobia related to MRI
  • Pregnancy
  • Heart failure classified as NYHA III or IV
  • Impaired kidney function with eGFR less than 30 ml/min or proteinuria over 1 g/24h
  • Liver disease with cirrhosis (Child-Pugh class C) or low albumin levels
  • Muscular dystrophies
  • Active cancer or severe conditions likely to affect survival or study participation
  • Unwillingness or inability to cooperate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Singapore General Hospital

Singapore, Singapore, 169608

Not Yet Recruiting

2

Duke NUS Medical School

Singapore, Singapore, 169857

Actively Recruiting

3

Changi General Hospital

Singapore, Singapore, 529889

Actively Recruiting

4

Sengkang General Hospital

Singapore, Singapore, 544886

Not Yet Recruiting

Loading map...

Research Team

T

Tzy Tiing Lim

CONTACT

M

Marton Adriana, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here